article thumbnail

Amvuttra RNAi Therapeutic Wins FDA Approval for Rare Genetic Protein Disorder

XTalks

Alnylam Pharmaceuticals, a leading RNA interference (RNAi) therapeutics biopharmaceutical company, announced it received approval from the US Food and Drug Administration (FDA) for its RNAi therapeutic Amvuttra (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (ATTR) amyloidosis in adults.

article thumbnail

Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19

Pfizer

I am grateful to have received four doses of the Pfizer-BioNTech vaccine and I am feeling well while experiencing very mild symptoms. I am incredibly grateful for the tireless efforts of my Pfizer colleagues who worked to make vaccines and treatments available for me and people around the world. COVID-19, Vaccines. 07.19.2022.

Drugs 99
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Key Trends in the Life Sciences to Look Forward to in 2022

XTalks

The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. The power of its real-world application was demonstrated by the resounding success of the mRNA COVID-19 vaccines. RNA in the Making.

article thumbnail

2020 review – Pharma’s progress outside of COVID-19

pharmaphorum

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. NT-814 is a non-hormonal drug that works on the neurokinin (NK) 1,3 receptor antagonist, thus treating the vasomotor symptoms associated with the menopause.

article thumbnail

Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVIDâ„¢ Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Pfizer

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

article thumbnail

Monthly News Roundup – December 2020

The Pharma Data

Moderna and Pfizer’s COVID-19 Vaccines Roll Out in Early Phase. Food and Drug Administration (FDA) issued Emergency Use Authorization for two COVID-19 vaccines: Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273. In studies, the vaccines were found to be 94% to 95% effective in preventing COVID-19 disease.

article thumbnail

Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVIDâ„¢ to Help Combat COVID-19

Pfizer

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Research Vaccines. COVID-19 Research Vaccines. Maternal Immunization Pediatrics Research Vaccines.

Drugs 110